Shanghai Braegen Pharmaceuticals

Braegen is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologics for cancer immunotherapy. With research facilities in both Shanghai and San Francisco, the company utilizes proprietary technology platforms to engineer next-generation therapies, including tumor-targeted cytokines and multi-specific antibodies. Its lead candidate, BJ-001, is a first-in-class IL-15 fusion protein designed to selectively activate immune cells within the tumor microenvironment while reducing systemic side effects. The company's pipeline also includes promising candidates targeting Claudin 18.2 and other validated oncology targets. Braegen is backed by prominent venture capital firms and aims to provide transformative treatment options for patients with advanced malignancies.